This highlights an additional anti-tumor effect of oncolytic reovirus, next to direct lysis of tumor cells, and this natural CAF tropism could be potentially exploited to select GI cancer patients for OV therapy based on the JAM-A expression of both the tumor and stromal cells. The gene discussed is F11R; the disease is neoplasm.